Articles with public access mandates - Chantale BernatchezLearn more
Not available anywhere: 3
Surgical approach does not influence changes in circulating immune cell populations following lung cancer resection
N Deboever, DJ McGrail, Y Lee, HT Tran, KG Mitchell, MB Antonoff, ...
Lung Cancer 164, 69-75, 2022
Mandates: US National Institutes of Health
Pulmonary resection for tissue harvest in adoptive tumor‐infiltrating lymphocyte therapy: Safety and feasibility
EM Corsini, KG Mitchell, N Zhou, C Bernatchez, MA Forget, CL Haymaker, ...
Journal of surgical oncology 124 (4), 699-703, 2021
Mandates: US National Institutes of Health
187 Multi-omic single-cell profiling demonstrates that competition for fatty acids and fatty acid oxidation enables tumor-infiltrating lymphocyte function and survival
MA Paniagua, C Haymaker, JR Adolacion, X An, C Creasy, M Fathi, R Ali, ...
Journal for ImmunoTherapy of Cancer 9 (Suppl 2), A199-A199, 2021
Mandates: US National Science Foundation, US National Institutes of Health, Cancer …
Available somewhere: 95
Loss of PTEN promotes resistance to T cell–mediated immunotherapy
W Peng, JQ Chen, C Liu, S Malu, C Creasy, MT Tetzlaff, C Xu, ...
Cancer discovery 6 (2), 202-216, 2016
Mandates: US National Institutes of Health
Loss of IFN-γ pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy
J Gao, LZ Shi, H Zhao, J Chen, L Xiong, Q He, T Chen, J Roszik, ...
Cell 167 (2), 397-404. e9, 2016
Mandates: US National Institutes of Health
A cancer cell program promotes T cell exclusion and resistance to checkpoint blockade
L Jerby-Arnon, P Shah, MS Cuoco, C Rodman, MJ Su, JC Melms, ...
Cell 175 (4), 984-997. e24, 2018
Mandates: US National Institutes of Health, Howard Hughes Medical Institute
Increased tumor glycolysis characterizes immune resistance to adoptive T cell therapy
T Cascone, JA McKenzie, RM Mbofung, S Punt, Z Wang, C Xu, ...
Cell metabolism 27 (5), 977-987. e4, 2018
Mandates: US Department of Defense, US National Institutes of Health
Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial
T Cascone, WN William Jr, A Weissferdt, CH Leung, HY Lin, A Pataer, ...
Nature medicine 27 (3), 504-514, 2021
Mandates: US National Institutes of Health
Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients
LG Radvanyi, C Bernatchez, M Zhang, PS Fox, P Miller, J Chacon, R Wu, ...
Clinical Cancer Research 18 (24), 6758-6770, 2012
Mandates: US National Institutes of Health
Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook
R Wu, MA Forget, J Chacon, C Bernatchez, C Haymaker, JQ Chen, P Hwu, ...
The Cancer Journal 18 (2), 160-175, 2012
Mandates: US National Institutes of Health
Oncogenic BRAF (V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma
JS Khalili, S Liu, TG Rodríguez-Cruz, M Whittington, S Wardell, C Liu, ...
Clinical Cancer Research 18 (19), 5329-5340, 2012
Mandates: US National Institutes of Health
Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer
J Blando, A Sharma, MG Higa, H Zhao, L Vence, SS Yadav, J Kim, ...
Proceedings of the National Academy of Sciences 116 (5), 1692-1697, 2019
Mandates: US National Institutes of Health
Identification of bacteria-derived HLA-bound peptides in melanoma
S Kalaora, A Nagler, D Nejman, M Alon, C Barbolin, E Barnea, ...
Nature 592 (7852), 138-143, 2021
Mandates: US National Institutes of Health, UK Medical Research Council, Wellcome …
Validation of multiplex immunofluorescence panels using multispectral microscopy for immune-profiling of formalin-fixed and paraffin-embedded human tumor tissues
ER Parra, N Uraoka, M Jiang, P Cook, D Gibbons, MA Forget, ...
Scientific reports 7 (1), 13380, 2017
Mandates: US National Institutes of Health
Comprehensive T cell repertoire characterization of non-small cell lung cancer
A Reuben, J Zhang, SH Chiou, RM Gittelman, J Li, WC Lee, J Fujimoto, ...
Nature communications 11 (1), 603, 2020
Mandates: US Department of Defense, US National Institutes of Health, Howard Hughes …
TCR repertoire intratumor heterogeneity in localized lung adenocarcinomas: an association with predicted neoantigen heterogeneity and postsurgical recurrence
A Reuben, R Gittelman, J Gao, J Zhang, EC Yusko, CJ Wu, R Emerson, ...
Cancer discovery 7 (10), 1088-1097, 2017
Mandates: US Department of Defense, US National Institutes of Health
Multimodal pooled Perturb-CITE-seq screens in patient models define mechanisms of cancer immune evasion
CJ Frangieh, JC Melms, PI Thakore, KR Geiger-Schuller, P Ho, ...
Nature genetics 53 (3), 332-341, 2021
Mandates: US National Institutes of Health, Howard Hughes Medical Institute
Costimulation through the CD137/4-1BB pathway protects human melanoma tumor-infiltrating lymphocytes from activation-induced cell death and enhances antitumor effector function
JA Hernandez-Chacon, Y Li, RC Wu, C Bernatchez, Y Wang, JS Weber, ...
Journal of immunotherapy 34 (3), 236-250, 2011
Mandates: US National Institutes of Health
BRAFV600E Co-opts a Conserved MHC Class I Internalization Pathway to Diminish Antigen Presentation and CD8+ T-cell Recognition of Melanoma
SD Bradley, Z Chen, B Melendez, A Talukder, JS Khalili, ...
Cancer immunology research 3 (6), 602-609, 2015
Mandates: US National Institutes of Health
Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy
M Sharma, H Khong, F Fa’ak, SE Bentebibel, LME Janssen, BC Chesson, ...
Nature communications 11 (1), 661, 2020
Mandates: US National Institutes of Health, Cancer Prevention Research Institute of …
Publication and funding information is determined automatically by a computer program